ProSomnus Comments on Insurance Coverage Policy Update for Obstructive and Central Sleep Apnea
PLEASANTON, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProSomnus, Inc. (NASDAQ: OSA) (the “Company”), the leading non-CPAP Obstructive Sleep Apnea...
Healthcare
Wave Life Sciences Highlights Recent Achievements and Upcoming 2024 Milestones
Multiple data catalysts across all clinical programs expected throughout 2024, including data for WVE-006 in AATD which would provide first-ever...
OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MIAMI, Jan. 08, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in...
Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2023 and Provides Initial 2024 Guidance
MINNEAPOLIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
Occlutech(R) Announces FDA Approval of its Occlutech(R) ASD Occluder and Occlutech(R) Pistol Pusher, a Minimally Invasive Cardiac Device and Delivery System to Treat Atrial Septal Defects
SCHAFFHAUSEN, CH / ACCESSWIRE / January 8, 2024 / Occlutech Holding AG Occlutech ASD Occluder delivers positive procedural outcomes with...
Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2024
– Revenue of $1,013.1 Million Exceeds Guidance – – 5.2% Organic Constant Currency Revenue Growth ex. COVID-19, also Exceeding Guidance...
Prevention Over Cure: The Benefits of Being Proactive Vs. Reactive When It Comes to Health
Live the Way is Pioneering An Evidence-Based Approach to Health and Well-BeingLAS VEGAS, NV / ACCESSWIRE / January 5, 2024...
Top 10 Morpheus8 Questions Being Asked About This Skin Procedure
NEWPORT BEACH, CA / ACCESSWIRE / January 5, 2024 / Morpheus8 is an innovative esthetic procedure that has gained popularity...
AngioDynamics Reports Fiscal Year 2024 Second Quarter Financial Results; Revises Fiscal Year 2024 Guidance
Fiscal Year 2024 Second Quarter Highlights Net sales of $79.1 million increased 2.7% on a pro-forma basis compared to the...
Metrodora Institute Announces New Chief Scientific Officer
Rohit Gupta, a Nationally Recognized Scientist, Biobank and Data Expert, is Named as Metrodora Institute's New Chief Scientific Officer and...
Healthcare Triangle, Inc. to Participate at the 2024 MUSE Executive Institute
PLEASANTON, Calif., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Healthcare Triangle, Inc. (Nasdaq: HCTI) (“Healthcare Triangle,” “HCTI” or the “Company”), a leader...
Axial Therapeutics to Present at Upcoming Conferences
WOBURN, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Axial Therapeutics, a clinical-stage biotechnology company dedicated to the development of gut-targeted,...
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
CORAL GABLES, Fla., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today...
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
Enrollment in dose escalation and backfill cohorts continuing in Phase 1 clinical trial of XMT-1660, Dolasynthen B7-H4 ADC; expect to...
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a...
Stryker to announce financial results for its fourth quarter and full year 2023
Portage, Michigan, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that it will report financial results for fourth quarter...
First ReWalk Personal Exoskeleton Claim Paid by Medicare
ReWalk Personal Exoskeleton covered as a medically necessary device for an eligible Medicare beneficiary with spinal cord injuryMARLBOROUGH, Mass. and...
Augmedix Exits Calendar 2023 with Expected $51 Million in Annual Recurring Revenue
Company Also Expects Fourth Quarter 2023 Revenue Above Guidance, Announces General Availability of Augmedix GoSAN FRANCISCO, Jan. 05, 2024 (GLOBE...
Compass Pathways and Greenbrook TMS enter into three-year research collaboration agreement
Three-year research collaboration will investigate the development of scalable, commercial delivery models for COMP360 psilocybin treatment, if FDA-approvedLONDON, Jan. 05,...
Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on...